Property Comparison
EPA & DHA (Targets)
Saturates & Monoenes (Impurities)
Why This Separation Works
EPA and DHA have a unique molecular geometry due to their multiple cis double bonds. Each double bond introduces a 30° kink in the carbon chain, giving EPA and DHA an irregular, non-linear shape. This single structural feature underlies all practical separation methods:
| Separation Basis | EPA/DHA Behavior | Saturates/Monoenes Behavior | Method |
|---|---|---|---|
| Urea adduct geometry | Kinked chains cannot fit in urea channels | Straight chains form tight urea inclusion complexes | Urea complexation |
| Boiling point | Higher BP than same-chain saturates (more MW) | Lower BP, distills first | Molecular distillation |
| pi-Electron affinity | 5–6 double bonds bind Ag+ strongly | 0–1 double bonds, weak Ag+ binding | Ag+ chromatography |
| CO2 solubility | More soluble in supercritical CO2 (higher polarity) | Less soluble at low pressure | Supercritical CO2 |
Crude anchovy or menhaden fish oil typically contains 10–30% EPA+DHA. Industrial processes combine 2–3 methods in sequence to achieve the >80% EPA+DHA required for pharmaceutical-grade omega-3 concentrates (e.g., Lovaza, Vascepa).
Recommended Process Route
Saponification and Ethyl Esterification
Saponify crude fish oil with 1 M KOH in ethanol (reflux, 1 hour) to release free fatty acids from triglycerides. Re-esterify as ethyl esters using anhydrous ethanol with H2SO4 catalyst (60°C, 2 hours). Ethyl esters (FA-OEt) have 15–30°C lower boiling points than the corresponding methyl esters or free acids, greatly improving downstream molecular distillation efficiency. Wash with water, dry over Na2SO4, and filter. Fatty acid profile by GC-FID (AOAC 996.06).
Feed preparationUrea Complexation (Selective Crystallization)
Dissolve the ethyl ester mixture and urea (4:1 urea:fatty acid w/w) together in hot ethanol (70°C). Cool the mixture slowly to 0–4°C overnight with gentle stirring. Straight-chain saturated and monounsaturated fatty acid esters (palmitate, stearate, oleate) form crystalline urea inclusion complexes — the linear carbon chains thread into the hexagonal urea channels. EPA and DHA ethyl esters, with their bent cis double bond geometry, cannot fit in the channels and remain in solution. Filter at 0°C: filter cake contains urea adducts (waste); filtrate is EPA+DHA-enriched. Dissolve filter cake in hot water to recover urea for reuse. Typical enrichment: from 25% to 55–65% EPA+DHA.
Key separation stepMolecular Distillation (Short-Path)
Subject the urea filtrate to short-path molecular distillation at 0.1–1 Pa and 180–220°C evaporator temperature. At these pressures, the mean free path of vapor molecules exceeds the evaporator-to-condenser distance, enabling separation without thermal decomposition. Shorter-chain and less-unsaturated fatty acids distill at lower temperature (distillate fraction); longer EPA and DHA ethyl esters remain in the residue at higher temperature. Fraction collection: distillate (palmitate, stearate) is waste; residue is EPA+DHA-enriched. Typical enrichment: from 55% to 75–85% EPA+DHA. Product is food/nutraceutical grade.
ConcentrationSilver-Ion Chromatography (Pharmaceutical Polishing)
For pharmaceutical-grade concentrates (>90% EPA+DHA by GC-FID, or pure EPA for Vascepa-type product), use Ag+-impregnated silica chromatography. Silver ions in the stationary phase form reversible π-complexes with carbon–carbon double bonds. Retention order: saturates < monoenes < dienes < trienes < tetraenes < EPA (5 double bonds) < DHA (6 double bonds). Elute with hexane:ethyl acetate or acetonitrile:water gradients. EPA and DHA elute at different retention times enabling their separation from each other as well as from remaining PUFA impurities. Column life: 50–100 cycles; silver leaching must be monitored and is below ICH limits for oral drugs.
PolishingAntioxidant Stabilization and Packaging
Add antioxidants immediately after the final purification step: mixed tocopherols (0.1–0.5% w/w), rosemary extract, or ascorbyl palmitate to prevent autoxidation of the highly unsaturated product. Nitrogen blanket all tanks, lines, and containers. Final product quality testing: peroxide value (PV <5 meq/kg), anisidine value (AV <20), total oxidation (TOTOX = 2PV+AV <26), fatty acid profile by GC-FID, heavy metals (ICP-MS), and dioxins/PCBs (high-resolution GC-MS).
Final productExpected Results
Pharmaceutical-grade EPA ethyl ester (Vascepa) requires >96% EPA by GC with <4% other fatty acids; achievable only with Ag+ chromatography after urea + molecular distillation. Nutraceutical-grade (>60% EPA+DHA) requires only urea complexation + molecular distillation and is produced at multi-thousand tonne scale by DSM, BASF (Pronova), and Croda.
Alternative Techniques
| Technique | Feasibility | Notes |
|---|---|---|
| Supercritical CO2 Extraction | Good | At 15–25 MPa and 40–50°C, supercritical CO2 preferentially extracts shorter-chain and more-saturated fatty acids. By pressure programming, EPA/DHA fraction can be enriched from 30% to ~60%. No solvent residue, GRAS for food. Higher capital cost than urea. Used by KD Pharma and others. |
| Enzymatic Enrichment | Good | Lipase-catalyzed selective esterification: saturated fatty acids react faster with glycerol than EPA/DHA (steric hindrance from cis double bonds near carboxyl group). Repeating esterification–hydrolysis cycles enriches EPA/DHA in the free acid fraction. Immobilized Candida antarctica Lipase B (Novozyme 435) most common. Combines well with molecular distillation. |
| Reversed-Phase HPLC | Moderate | C18 silica separates fatty acid ethyl esters by chain length and unsaturation. EPA and DHA are baseline-resolved from most other PUFA. Not practical at large scale (high solvent consumption). Used analytically and for small-batch high-purity research standards. |
| Low-Temperature Crystallization | Moderate | Cool fish oil to −70°C. Saturated and monounsaturated triglycerides crystallize (higher melting point) and can be filtered off. EPA and DHA remain liquid. Simpler than urea complexation but requires very low temperatures and gives lower enrichment (<50% EPA+DHA). |
| Membrane Fractionation | Poor | All fatty acids in fish oil have very similar MW (250–340 Da) and are all hydrophobic. Membrane separation by size or charge gives negligible selectivity. Dense ceramic membranes in organic solvents can provide limited selectivity but not at industrially useful levels. |
Frequently Asked Questions
Why do EPA and DHA not form urea inclusion complexes while saturated fats do?
Urea forms hexagonal crystalline channels with an internal diameter of approximately 5.2 Å (angstroms). Straight-chain saturated fatty acids in their extended all-trans conformation fit perfectly inside these channels, stabilized by van der Waals interactions. Each cis double bond in EPA and DHA introduces a ~30° kink in the carbon chain. With 5 double bonds, EPA has a highly curved geometry that simply cannot fit into the straight urea channels. The thermodynamic driving force for urea adduct formation is absent for EPA/DHA, so they remain in the liquid ethanol filtrate while saturates crystallize. This selectivity is remarkably effective: urea complexation can reduce C16:0 and C18:0 content from >30% to <2% in a single pass.
How does silver-ion chromatography separate EPA from DHA?
Silver ions (Ag+) form reversible π-complexes with the electrons in carbon–carbon double bonds. The binding strength increases with the number of double bonds: DHA (6 double bonds, 22 carbons) binds more strongly to Ag+-silica than EPA (5 double bonds, 20 carbons). This ~20% difference in binding affinity, combined with the 2 Da MW difference, gives sufficient resolution for baseline separation by gradient elution. The key advantage over reversed-phase HPLC is that silver-ion chromatography can separate by degree of unsaturation independent of chain length, cleanly separating C22:6 (DHA) from C22:5 (DPA, docosapentaenoic acid) which co-elute on C18 columns.
What is the regulatory pathway for pharmaceutical omega-3 concentrates?
EPA and DHA ethyl ester concentrates are approved as prescription drugs in several markets: Lovaza (omega-3-acid ethyl esters, 84% EPA+DHA, GSK/AstraZeneca) for hypertriglyceridemia in the US (FDA 2004), and Vascepa (icosapent ethyl, >96% EPA ethyl ester, Amarin) for cardiovascular risk reduction (FDA 2019). The MARINE and REDUCE-IT clinical trials established the cardiovascular benefit. Manufacturing must comply with ICH Q7 (GMP for active pharmaceutical ingredients), with full characterization of impurities, residual solvents (ICH Q3C), and elemental impurities including residual silver from Ag+ chromatography (ICH Q3D Oral PDE: 1,500 μg/day).
Why must omega-3 products be protected from oxidation during processing?
EPA and DHA are among the most easily oxidized lipids in nature. Each of their 5–6 cis double bonds is a site for free radical chain reaction oxidation (autoxidation). Oxidized omega-3s not only lose their bioactive properties but generate toxic aldehydes (4-HNE, malondialdehyde) and unpleasant fishy odors (hexanal, nonanal). The oxidation rate is proportional to the number of double bonds and to temperature. Processing must be conducted under nitrogen or argon atmosphere with minimal exposure to light and heat, and antioxidants must be added immediately after each purification step. The GOED (Global Organization for EPA and DHA Omega-3s) voluntary monograph specifies PV <5 meq/kg, AV <20, and TOTOX <26 for finished products.
Related Separation Guides
Simulate This Process Yourself
Build the omega-3 concentration process in untangle.bio with drag-and-drop, model each enrichment step, and optimize EPA+DHA yield and purity for your feedstock.
Open untangle.bio